Summary
Global Markets Direct’s, ‘Indolent Lymphoma - Pipeline Review, H2 2016’, provides an overview of the Indolent Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
- The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc
Affimed GmbH
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
MorphoSys AG
Novartis AG
Seattle Genetics, Inc.
Trillium Therapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Indolent Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Indolent Lymphoma - Overview 11
Indolent Lymphoma - Therapeutics under Development by Companies 12
Indolent Lymphoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Indolent Lymphoma - Products under Development by Companies 16
Indolent Lymphoma - Companies Involved in Therapeutics Development 18
AbbVie Inc 18
Affimed GmbH 19
Altor BioScience Corporation 20
Amgen Inc. 21
Astellas Pharma Inc. 22
Bayer AG 23
Boehringer Ingelheim GmbH 24
Bristol-Myers Squibb Company 25
Celgene Corporation 26
Eli Lilly and Company 27
F. Hoffmann-La Roche Ltd. 28
Gilead Sciences, Inc. 29
Incyte Corporation 30
Infinity Pharmaceuticals, Inc. 31
Juno Therapeutics Inc. 32
MedImmune, LLC 33
Merck & Co., Inc. 34
Merck KGaA 35
Millennium Pharmaceuticals Inc 36
MorphoSys AG 37
Novartis AG 38
Seattle Genetics, Inc. 39
Trillium Therapeutics Inc. 40
Indolent Lymphoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
AFM-11 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ALT-803 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
bendamustine hydrochloride - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
BI-836826 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
blinatumomab - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
BMS-986016 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
BTH-1677 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
CC-122 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
copanlisib hydrochloride - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
DI-B4 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
duvelisib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
entospletinib - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
ibrutinib - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
INCB-40093 - Drug Profile 127
Product Description 127
Mechanism Of Action 127
R&D Progress 127
INCB-50465 - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
inebilizumab - Drug Profile 129
Product Description 129
Mechanism Of Action 129
R&D Progress 129
inebilizumab + MEDI-0680 - Drug Profile 131
Product Description 131
Mechanism Of Action 131
R&D Progress 131
itacitinib adipate - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
JCAR-014 - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
JCAR-015 - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
JCAR-017 - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
lenalidomide - Drug Profile 146
Product Description 146
Mechanism Of Action 146
R&D Progress 146
LY-3023414 - Drug Profile 160
Product Description 160
Mechanism Of Action 160
R&D Progress 160
MOR-208 - Drug Profile 162
Product Description 162
Mechanism Of Action 162
R&D Progress 162
obinutuzumab - Drug Profile 167
Product Description 167
Mechanism Of Action 167
R&D Progress 167
ofatumumab - Drug Profile 174
Product Description 174
Mechanism Of Action 174
R&D Progress 174
SEA-CD40 - Drug Profile 182
Product Description 182
Mechanism Of Action 182
R&D Progress 182
TAK-659 - Drug Profile 183
Product Description 183
Mechanism Of Action 183
R&D Progress 183
TTI-621 - Drug Profile 184
Product Description 184
Mechanism Of Action 184
R&D Progress 184
venetoclax - Drug Profile 187
Product Description 187
Mechanism Of Action 187
R&D Progress 187
vorinostat - Drug Profile 196
Product Description 196
Mechanism Of Action 196
R&D Progress 196
Indolent Lymphoma - Dormant Projects 200
Indolent Lymphoma - Discontinued Products 202
Indolent Lymphoma - Product Development Milestones 203
Featured News & Press Releases 203
Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society 203
Nov 30, 2015: New Data from Bayer’s Portfolio in Oncology to be Presented at ASH 2015 203
Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 203
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 204
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 204
Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 206
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 207
Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 208
Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 210
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213
List of Tables
Number of Products under Development for Indolent Lymphoma, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Indolent Lymphoma - Pipeline by AbbVie Inc, H2 2016 18
Indolent Lymphoma - Pipeline by Affimed GmbH , H2 2016 19
Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016 20
Indolent Lymphoma - Pipeline by Amgen Inc., H2 2016 21
Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016 22
Indolent Lymphoma - Pipeline by Bayer AG, H2 2016 23
Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 24
Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 25
Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2016 26
Indolent Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 27
Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28
Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 29
Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2016 30
Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 31
Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 32
Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2016 33
Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 34
Indolent Lymphoma - Pipeline by Merck KGaA, H2 2016 35
Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 36
Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2016 37
Indolent Lymphoma - Pipeline by Novartis AG, H2 2016 38
Indolent Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 39
Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Assessment by Combination Products, H2 2016 42
Number of Products by Stage and Target, H2 2016 44
Number of Products by Stage and Mechanism of Action, H2 2016 47
Number of Products by Stage and Route of Administration, H2 2016 50
Number of Products by Stage and Molecule Type, H2 2016 52
Indolent Lymphoma - Dormant Projects, H2 2016 200
Indolent Lymphoma - Dormant Projects (Contd..1), H2 2016 201
Indolent Lymphoma - Discontinued Products, H2 2016 202
List of Figures
Number of Products under Development for Indolent Lymphoma, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 15
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Top 10 Targets, H2 2016 43
Number of Products by Stage and Top 10 Targets, H2 2016 43
Number of Products by Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Routes of Administration, H2 2016 49
Number of Products by Stage and Routes of Administration, H2 2016 49
Number of Products by Molecule Types, H2 2016 51
Number of Products by Stage and Molecule Types, H2 2016 51
